GlassScriptPhysician profile
Brooke Sikora
NPI 1760682553
$23,461.16
in general payments reported to CMS, 2019-2025
28 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,415 · 2021: $1,054 · 2022: $822 · 2023: $901 · 2024: $1,203 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $12,505.70 | 2019-2025 | Aklief |
| Aclaris Therapeutics, INC. | $2,962.39 | 2019 | |
| Allergan, INC. | $2,296.83 | 2019-2022 | |
| Abbvie INC. | $916.93 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $655.43 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $493.17 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $429.32 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $348.10 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $319.21 | 2019-2025 | |
| Janssen Biotech, INC. | $296.77 | 2019-2025 | Tremfya |
| Genzyme Corporation | $282.68 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $240.54 | 2019-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $217.58 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $215.53 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $201.78 | 2021-2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $185.62 | 2019 | |
| Pfizer INC. | $138.90 | 2019-2023 | |
| Dermira, INC. | $120.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.22 | 2022-2024 | Spevigo |
| Revance Therapeutics, INC. | $95.17 | 2024 | Daxxify |
| Genentech USA, INC. | $94.43 | 2019-2024 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.83 | 2020-2021 | |
| Celgene Corporation | $86.66 | 2019 | |
| Mission Pharmacal Company | $45.60 | 2019 | |
| Arcutis Biotherapeutics, INC. | $35.52 | 2023 | |
| Organon LLC | $34.72 | 2025 | |
| Botanix Sb INC | $29.64 | 2025 | Sofdra |
| Mylan Pharmaceuticals INC. | $18.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Sikora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.